Avenacy Announces Launch of Desmopressin Acetate for Injection in the U.S. Market
Retrieved on:
Monday, April 15, 2024
Hospitals, Pharmaceutical, Health, Cardiology, FDA, Administration, Boxed warning, Respiratory arrest, Injury, Bleeding, Risk, Factor VIII, Food, Hemarthrosis, Warning, Hyponatremia, Death, Polydipsia, Seizure, Contraindication, Patient, Diabetes insipidus, Central diabetes insipidus, Haemophilia, Coma, Pharmaceutical industry
Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Desmopressin Acetate for Injection in the United States as a therapeutic equivalent generic for DDAVP® for Injection (Desmopressin Acetate) approved by the U.S. Food and Drug Administration.
Key Points:
- Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Desmopressin Acetate for Injection in the United States as a therapeutic equivalent generic for DDAVP® for Injection (Desmopressin Acetate) approved by the U.S. Food and Drug Administration.
- Desmopressin Acetate for Injection is multi-indicated for patients with central diabetes insipidus, hemophilia A, and von Willebrand’s disease (Type I).
- View the full release here: https://www.businesswire.com/news/home/20240415847399/en/
Avenacy’s Desmopressin Acetate for Injection is available in two presentations: 4 mcg per 1 mL single-dose vials, and 40 mcg per 10 mL multiple-dose vials. - Avenacy will begin shipping Desmopressin Acetate for Injection to wholesale partners this week.